An update from Teleflex ( ($TFX) ) is now available.
On May 9, 2025, Teleflex Incorporated’s Board of Directors approved amendments to the company’s bylaws, specifically removing a section that required stockholder actions to occur only at official meetings. This change could impact how stockholder decisions are made in the future. Additionally, during the 2025 annual meeting, stockholders voted on various proposals, including the election of directors and executive compensation, with most proposals receiving majority approval, except for a stockholder proposal on special meeting requirements.
The most recent analyst rating on ($TFX) stock is a Buy with a $285.00 price target. To see the full list of analyst forecasts on Teleflex stock, see the TFX Stock Forecast page.
Spark’s Take on TFX Stock
According to Spark, TipRanks’ AI Analyst, TFX is a Neutral.
Teleflex’s solid financial performance is offset by technical indicators pointing towards bearish sentiment and perceived overvaluation. Strategic initiatives and acquisitions offer potential long-term growth, but near-term challenges such as revenue declines and operational pressures weigh down the outlook.
To see Spark’s full report on TFX stock, click here.
More about Teleflex
Teleflex Incorporated operates in the medical technology industry, providing products and services primarily focused on critical care and surgical applications. The company is known for its innovative solutions in vascular access, anesthesia, and surgical instruments, serving healthcare providers globally.
Average Trading Volume: 1,217,016
Technical Sentiment Signal: Sell
Current Market Cap: $5.6B
For a thorough assessment of TFX stock, go to TipRanks’ Stock Analysis page.
